In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors

Fahima Dossa¹, Chandrajit P Raut¹, Andrew J Wagner¹+10

• ¹Fahima Dossa, MD, PhD, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA; Chandrajit P. Raut, MD, Department of Surgery, Mass General Brigham, Harvard Medical School, Boston, MA; Andrew J. Wagner, MD, PhD, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Robin L. Jones, MD, Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom; Rebecca A. Gladdy, MD, PhD, Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Abha A. Gupta, MD, Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Kenneth Cardona, MD, Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA; David E. Gyorki, MD, Division of Cancer Surgery, Peter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Tom W. Chen, MD, PhD, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Herbert H. Loong, MBBS, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China; Sylvie Bonvalot, MD, PhD, Department of Surgical Oncology, Institut Curie, Paris, France; Silvia Stacchiotti, MD, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; and Alessandro Gronchi, MD, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.